Donatella Gemma

Publications

Title Published on Year
529P Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective “ReTrITA” study ANNALS OF ONCOLOGY 2024
73P Efficacy outcomes in ≥70-year-old or younger patients receiving regorafenib-to-trifluridine/tipiracil sequence or vice versa for refractory metastatic colorectal cancer: Findings from the multicenter retrospective “ReTrITA” study ANNALS OF ONCOLOGY 2024
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study ANNALS OF ONCOLOGY 2023
398P Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment ANNALS OF ONCOLOGY 2022
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA ONCOLOGY 2018

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma